Observational study on extensive-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study follows patients with extensive-stage small cell lung cancer to learn more about how different treatments work in real life. It may help doctors understand which treatments are most effective, and you may be able to contribute to improving care for others with the same condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been diagnosed with small cell lung cancer that has spread to other parts of the body (extensive stage).
- You are planning to receive any type of cancer treatment, such as chemotherapy or immunotherapy.
- You are willing to participate in the study and attend follow-up visits.
- You are expected to live for at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This observational study collects information and lab samples from people with extensive-stage small cell lung cancer. It may help researchers understand how patients respond and improve future care, but it usually does not add new treatment for you.
This trial tests a combination of three drugs—an immunotherapy (adebrelimab), a targeted therapy (famitinib), and chemotherapy—for people with extensive-stage small cell lung cancer. The goal is to see if this triple combination works better than standard treatment.
This trial tests a new combination treatment for extensive-stage small cell lung cancer: intensive chemotherapy plus an immunotherapy drug (adebrelimab), followed by a stem cell transplant using your own cells. The goal is to see if this powerful approach can shrink tumors and help you live longer.
This study looks at immune-related blood/tissue markers to understand disease activity in people with extensive-stage small cell lung cancer after standard upfront treatment. If your cancer fits the pattern they’re studying, it may help researchers improve how future treatments are matched to patients.
This Phase 2 trial tests how well two study drugs (and a combination of them) work in people with extensive-stage small cell lung cancer. It’s mainly for patients whose cancer has come back or who couldn’t tolerate at least some standard treatments, and it aims to see if treatment can shrink tumors and be tolerable.
This trial tests a combination of two experimental immunotherapy drugs (ivonescimab and cadonilimab) with standard chemotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this combination works better than chemo alone.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.